• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Kymera Therapeutics Inc.

    2/26/26 7:34:02 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KYMR alert in real time by email
    S-8 1 d15670ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on February 26, 2026

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    KYMERA THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   81-2992166
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

    500 North Beacon Street, 4th Floor

    Watertown, MA

      02472
    (Address of Principal Executive Offices)   (Zip Code)

     

     

    Kymera Therapeutics, Inc. 2020 Stock Option and Incentive Plan

    Kymera Therapeutics, Inc. Amended and Restated 2020 Employee Stock Purchase Plan

    (Full title of the plan)

     

     

    Nello Mainolfi, Ph.D.

    Founder, President and Chief Executive Officer

    Kymera Therapeutics, Inc.

    500 North Beacon Street, 4th Floor

    Watertown, MA 02472

    (Name and address of agent for service)

    (857) 285-5300

    (Telephone number, including area code, of agent for service)

     

     

    Copies to:

    William D. Collins, Esq.

    Catherine Magazu, Esq.

    Goodwin Procter LLP

    100 Northern Avenue

    Boston, Massachusetts 02210

    (617) 570-1000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 registers (i) 3,885,551 additional shares of common stock, $0.0001 par value per share (the “Common Stock”), of Kymera Therapeutics, Inc. (the “Company”) under the Kymera Therapeutics, Inc. 2020 Stock Option and Incentive Plan, as amended (the “Plan”) and (ii) 438,898 additional shares of Common Stock under the Kymera Therapeutics, Inc. Amended and Restated 2020 Employee Stock Purchase Plan (the “ESPP”). The additional shares are of the same class as other securities relating to the Plan and the ESPP for which the Registrant’s registration statements filed on Form S-8 filed with the Securities and Exchange Commission on August 21, 2020 (File No. 333-248249), March 11, 2021 (File No. 333-254122), February 24, 2022 (File No.  333-262947), February 23, 2023 (File No.  333-269928), February 22, 2024 (File No.  333-277242) and February 27, 2025 (File No. 333-285308) are effective. The information contained in the Registrant’s registration statements on Form S-8 (Registration Nos. 333-248249, 333-254122, 333-262947, 333-269928, 333-277242 and 333-285308) are hereby incorporated by reference pursuant to General Instruction E.


    Part II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 8. Exhibits.

     

    Exhibit
    No.
       Description
      4.1    Fourth Amended and Restated Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-39460) filed with the Securities and Exchange Commission on August 25, 2020.
      4.2    Second Amended and Restated Bylaws of the Registrant (Incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-39460) filed with the Securities and Exchange Commission on August 25, 2020.
      4.3    Specimen Common Stock Certificate of the Registrant (Incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-240264) filed with the Securities and Exchange Commission on August 17, 2020).
      4.4    Registration Rights Agreement by and among the Registrant and certain of its stockholders dated June  26, 2025 (Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No.  001-39460) filed with the Securities and Exchange Commission on June 27, 2025.
      5.1*    Opinion of Goodwin Procter LLP.
     23.1*    Consent of Ernst & Young LLP, independent registered public accounting firm.
     23.2*    Consent of Goodwin Procter LLP (included in Exhibit 5.1).
     24.1*    Power of Attorney (included on signature page).
     99.1    2020 Stock Option and Incentive Plan and forms of award agreements thereunder (Incorporated by reference to Exhibit 10.2 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-240264) filed with the Securities and Exchange Commission on August 17, 2020). 
     99.2    Amendment No.  1 to the 2020 Stock Option and Incentive Plan (Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No.  001-39460) filed with the Securities and Exchange Commission on June 20, 2024).
     99.3    Amended and Restated 2020 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-39460) filed with the Securities and Exchange Commission on November 5, 2020). 
    107*    Filing Fee Table.
     
    *

    Filed herewith.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Watertown, Commonwealth of Massachusetts, on February 26, 2026.

     

    KYMERA THERAPEUTICS, INC.
    By:   /s/ Nello Mainolfi
      Name: Nello Mainolfi, Ph.D.
      Title:  Founder, President and Chief Executive Officer

    POWER OF ATTORNEY AND SIGNATURES

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Nello Mainolfi, Ph.D. and Bruce Jacobs, CFA, MBA as such person’s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them, for such person in such person’s name, place and stead, in any and all capacities, to sign for us and in our names in the capacities indicated below the Registration Statement on Form S-8 of Kymera Therapeutics, Inc., and any or all amendments (including post-effective amendments), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in connection therewith and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.


    Signature    Title   Date

    /s/ Nello Mainolfi

    Nello Mainolfi, Ph.D.

      

    Director, Founder, President and Chief Executive Officer

    (Principal Executive Officer)

      February 26, 2026

    /s/ Bruce Jacobs

    Bruce Jacobs, CFA, MBA

      

    Chief Financial Officer

    (Principal Financial Officer)

    (Principal Accounting Officer)

      February 26, 2026

    /s/ Jeffrey Albers

    Jeffrey Albers, J.D., MBA

      

    Director

      February 26, 2026

    /s/ Felix J. Baker

    Felix J. Baker, Ph.D.

      

    Director

      February 26, 2026

    /s/ Bruce Booth

    Bruce Booth, D.Phil.

      

    Director

      February 26, 2026

    /s/ Pamela Esposito

    Pamela Esposito, Ph.D.

      

    Director

      February 26, 2026

    /s/ Gorjan Hrustanovic

    Gorjan Hrustanovic, Ph.D.

      

    Director

      February 26, 2026

    /s/ John Maraganore

    John Maraganore, Ph.D.

      

    Director

      February 26, 2026

    /s/ Elena Ridloff

    Elena Ridloff, CFA

      

    Director

      February 26, 2026

    /s/ Victor Sandor

    Victor Sandor, M.D

      

    Director

      February 26, 2026
    Get the next $KYMR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KYMR

    DatePrice TargetRatingAnalyst
    1/28/2026$133.00Overweight
    Barclays
    1/6/2026Outperform → Peer Perform
    Wolfe Research
    11/3/2025$90.00Buy
    Guggenheim
    10/24/2025$60.00 → $80.00Buy
    B. Riley Securities
    10/21/2025$81.00Outperform
    Mizuho
    9/18/2025$60.00 → $70.00Buy
    H.C. Wainwright
    9/17/2025$60.00Overweight
    Barclays
    9/16/2025$70.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $KYMR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

    KT-621 (STAT6) BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with data expected in late-2027 Initiated dosing in KT-579 (IRF5) Phase 1 healthy volunteer trial with data expected in 2H26 Dr. Neil Graham, experienced biopharma leader, appointed Chief Development Officer Well-capitalized with $1.6 billion in cash as of December 31, 2025, and runway into 2029 Company to hold video conference call and webcast today at 8:30 a.m. ET WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral

    2/26/26 7:00:00 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kymera Therapeutics to Participate in Upcoming March Investor Conferences

    WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:  TD Cowen 46th Annual Healthcare Conference in Boston, MA on March 3 at 9:10 a.m. ET;Leerink Partners Global Healthcare Conference in Miami, FL on March 10 at 11:20 a.m. ET; andBarclays 28th Annual Global Healthcare Conference in Miami, FL on March 12 at 9:30 a.m. ET. In addition, the Company will participate in the UBS Biotech Summit Miami and Jefferies

    2/24/26 7:00:00 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    WATERTOWN, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report fourth quarter and full year 2025 financial results on February 26, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this link, or visit "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the webcast will be archived and available following the event. About Kymera TherapeuticsKymera is a

    2/19/26 7:00:00 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYMR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Mainolfi Nello sold $2,707,813 worth of shares (30,000 units at $90.26) and exercised 30,000 shares at a strike of $2.08 (SEC Form 4)

    4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

    2/25/26 5:24:18 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Esposito Pamela exercised 2,500 shares at a strike of $49.10 and sold $218,270 worth of shares (2,500 units at $87.31) (SEC Form 4)

    4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

    2/20/26 5:30:08 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Esposito Pamela exercised 5,500 shares at a strike of $39.34 and sold $373,521 worth of shares (5,500 units at $67.91) (SEC Form 4)

    4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

    1/20/26 6:30:24 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYMR
    SEC Filings

    View All

    SEC Form 8-K filed by Kymera Therapeutics Inc.

    8-K - Kymera Therapeutics, Inc. (0001815442) (Filer)

    2/26/26 8:22:15 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by Kymera Therapeutics Inc.

    424B3 - Kymera Therapeutics, Inc. (0001815442) (Filer)

    2/26/26 8:18:01 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by Kymera Therapeutics Inc.

    424B5 - Kymera Therapeutics, Inc. (0001815442) (Filer)

    2/26/26 8:14:44 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYMR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on Kymera Therapeutics with a new price target

    Barclays resumed coverage of Kymera Therapeutics with a rating of Overweight and set a new price target of $133.00

    1/28/26 7:18:07 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kymera Therapeutics downgraded by Wolfe Research

    Wolfe Research downgraded Kymera Therapeutics from Outperform to Peer Perform

    1/6/26 8:41:07 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim resumed coverage on Kymera Therapeutics with a new price target

    Guggenheim resumed coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $90.00

    11/3/25 9:08:29 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYMR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baker Bros. Advisors Lp bought $172,499,918 worth of shares (2,005,813 units at $86.00) (SEC Form 4)

    4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

    12/11/25 4:19:37 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Bvf Partners L P/Il bought $13,955,348 worth of shares (317,167 units at $44.00) (SEC Form 4)

    4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

    7/1/25 6:41:37 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Baker Bros. Advisors Lp bought $28,842,000 worth of shares (655,500 units at $44.00) (SEC Form 4)

    4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

    6/30/25 8:15:05 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYMR
    Leadership Updates

    Live Leadership Updates

    View All

    Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary

    WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Brian Adams, JD, as Chief Legal Officer and Corporate Secretary. Mr. Adams is a highly accomplished legal executive with nearly two decades of leadership in the life sciences, spanning corporate development, strategic planning, and governance. He will lead Kymera's legal, governance, and intellectual property functions. Mr. Adams will succeed Ellen Chiniara who is retiring from her role to focus on board service, mentoring and oth

    9/3/25 7:00:00 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025

    WATERTOWN, Mass., May 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the Phase 1 clinical trial evaluating single and multiple-ascending doses of KT-621 in healthy volunteers on Monday, June 2, 2025. The Company will host a video webcast at 8:00 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this link, or visit "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the webcast and copy of the presentation will be a

    5/30/25 4:01:00 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases

    IRF5 program strengthens Kymera's oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a historically undrugged transcription factor and master regulator of immunity, has strong genetic and clinical pathway validation across multiple diseases including RA, SLE, IBD and others KT-579, a potent, selective, oral degrader of IRF5 with an excellent profile in preclinical safety studies, has demonstrated activity comparable or superior to approved and clinically active drugs in multiple efficacy animal models of lupus and RA IND-enabling studies are ongoing with Phase 1 testing expected to

    5/9/25 7:01:00 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYMR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kymera Therapeutics Inc.

    SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

    11/14/24 4:31:20 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kymera Therapeutics Inc.

    SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

    11/14/24 1:22:39 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kymera Therapeutics Inc.

    SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

    11/14/24 9:30:22 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KYMR
    Financials

    Live finance-specific insights

    View All

    Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

    KT-621 (STAT6) BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with data expected in late-2027 Initiated dosing in KT-579 (IRF5) Phase 1 healthy volunteer trial with data expected in 2H26 Dr. Neil Graham, experienced biopharma leader, appointed Chief Development Officer Well-capitalized with $1.6 billion in cash as of December 31, 2025, and runway into 2029 Company to hold video conference call and webcast today at 8:30 a.m. ET WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral

    2/26/26 7:00:00 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    WATERTOWN, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report fourth quarter and full year 2025 financial results on February 26, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this link, or visit "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the webcast will be archived and available following the event. About Kymera TherapeuticsKymera is a

    2/19/26 7:00:00 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis

    KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation from healthy volunteers to atopic dermatitis (AD) patients KT-621 achieved strong reductions in disease-relevant Type 2 biomarkers in blood, including TARC (median reduction of 74% in patients with baseline TARC levels comparable to dupilumab AD studies), Eotaxin-3, IL-31, IgE, and in core Type 2 inflammation and AD disease-relevant gene sets in skin lesions Robust clinical activity was observed across all disease endpoints measured including mean 63% EASI reduction and mean 40% peak pruritus NR

    12/8/25 7:00:00 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care